A new Suprimun clinical study conducted in Uruguayan patients

Laboratorios Clausen SA is pleased to report that it has completed a new clinical study in Uruguay that records the clinical experience with Suprimun/Micoflavin/Myclausen.

This is a descriptive, retrospective, comparative, including renal transplant patients between January 2005 and July 2010 by the same medical team from two institutions providing assistance given users the same brand of mycophenolate mofetil (MMF): A Generic MMF (Suprimun ®) and other innovative MMF. All patients were older than 18 years, attending his first kidney transplant and received a triple immunosuppression protocol, comprising: calcineurin inhibitor, steroids and MMF.

We compared the evolution of the two groups of patients and grafts All completed at least 6 months duration after renal transplantation.

Gonzalez-Martínez F, Orihuela S, Orihuela N, Manzo L, Núñez N, Nin M. Instituto de Nefrologia y Urología, Montevideo, Uruguay.